Ani Pharmaceuticals (ANIP) Other Non Operating Income (2011 - 2026)

Ani Pharmaceuticals has disclosed Other Non Operating Income across 16 years of filings, most recently posting -$651000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$651000.0, down 428.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $4000.0 (up 100.11% YoY), and the FY2024 annual result was -$4.0 million, down 2436.48% from the prior year.
• Other Non Operating Income came in at -$651000.0 for Q1 2026 at Ani Pharmaceuticals, up from -$1.1 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.7 million in Q2 2025 to a low of -$2.5 million in Q3 2024.
• The 5-year median for Other Non Operating Income is -$42000.0 (2022), against an average of -$218733.3.
• Across the five-year window, Other Non Operating Income plunged 4075.76% in 2024 and surged 2076.14% in 2025, its largest moves.
• Ani Pharmaceuticals' Other Non Operating Income stood at -$42000.0 in 2022, then grew by 21.43% to -$33000.0 in 2023, then slumped by 4075.76% to -$1.4 million in 2024, then rose by 21.34% to -$1.1 million in 2025, then jumped by 39.94% to -$651000.0 in 2026.
• The last three Other Non Operating Income figures came in at -$651000.0 (Q1 2026), -$1.1 million (Q4 2025), and $1.7 million (Q2 2025), per Business Quant data.